

# Trevi Therapeutics to Present at 2021 BIO Digital Conference

NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- [Trevi Therapeutics, Inc.](#) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Jennifer Good, President and CEO, has been selected to deliver a company presentation at [2021 BIO Digital](#). For 2021, the BIO International Convention will be held virtually as BIO Digital, on June 10 and 11 and from June 14-18.

The Company's presentation will be available to registered BIO Digital attendees from 9am ET June 10, until the end of the conference on June 18.

An archived replay of the presentation will be available for 30 days following the conclusion of the conference by visiting 'News & Events' in the 'Investors & News' section on the Company's website at [www.trevitherapeutics.com](http://www.trevitherapeutics.com).

## About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

## About Haduvio

Haduvio, an investigational therapy, is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed  $\kappa$ -opioid receptor agonist and  $\mu$ -opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The  $\kappa$ - and  $\mu$ -opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with  $\mu$ -opioid agonists because it antagonizes, or blocks,  $\mu$ -opioid receptors. Nalbuphine is not currently classified as a controlled substance by the DEA in the United States and by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Haduvio is an investigational therapy that has been granted Fast Track designation by FDA for the proposed indication of reduction of moderate to severe pruritus in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

## Investor Contact

Katie McManus  
Trevi Therapeutics, Inc.  
203-304-2499  
[k.mcmanus@trevitherapeutics.com](mailto:k.mcmanus@trevitherapeutics.com)

## Media Contact

Rosalia Scampoli  
914-815-1465  
[rscampoli@marketcompr.com](mailto:rscampoli@marketcompr.com)

SOURCE Trevi Therapeutics, Inc.

---

<https://ir.trevitherapeutics.com/2021-06-09-Trevi-Therapeutics-to-Present-at-2021-BIO-Digital-Conference>